autologous regulatory T cell product

Autologous regulatory T cell product refers to a personalized cellular immunotherapy in which a patient’s own (autologous) CD4+CD25+FOXP3+ regulatory T cells (Tregs) are isolated, expanded ex vivo, and then reinfused to modulate immune responses. These products are designed to restore immune tolerance and suppress pathological immune activity by increasing the proportion of functional Tregs relative to effector or pathogenic immune cells. The mechanism of action is primarily through immunosuppression—Tregs downregulate activation and proliferation of effector lymphocytes via contact-dependent mechanisms and secretion of anti-inflammatory cytokines such as IL-10 and transforming growth factor beta (TGF-β)[2][1]. Autologous products minimize the risk of rejection since they originate from the same individual[3][10]. Clinical trials have investigated their use in autoimmune diseases (e.g., type 1 diabetes, multiple sclerosis), solid organ transplantation (to prevent rejection or reduce need for pharmacologic immunosuppression), graft-versus-host disease after hematopoietic stem cell transplantation, idiopathic aplastic anemia, lupus, Crohn’s disease, ulcerative colitis, pemphigus vulgaris[5][6][8]. Manufacturing involves leukapheresis followed by isolation and expansion under GMP conditions; some protocols include genetic engineering for tissue specificity or enhanced function[1][3]. Early-phase clinical studies indicate safety and feasibility; efficacy is under active investigation.

Other names

autologous Treg therapyautologous regulatory T cellsexpanded autologous regulatory T cellsadoptive regulatory T cell therapy